These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25634208)

  • 21. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.
    Nichols AC; Yoo J; Palma DA; Fung K; Franklin JH; Koropatnick J; Mymryk JS; Batada NN; Barrett JW
    Arch Otolaryngol Head Neck Surg; 2012 Aug; 138(8):732-9. PubMed ID: 22911296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis.
    Geurts TW; van Velthuysen ML; Broekman F; van Huysduynen TH; van den Brekel MW; van Zandwijk N; van Tinteren H; Nederlof P; Balm AJ; Brakenhoff RH
    Clin Cancer Res; 2009 Feb; 15(3):980-5. PubMed ID: 19188169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas.
    Waitzberg AF; Nonogaki S; Nishimoto IN; Kowalski LP; Miguel RE; Brentani RR; Brentani MM
    Cancer Detect Prev; 2004; 28(3):178-86. PubMed ID: 15225897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein.
    Leng K; Schlien S; Bosch FX
    J Oral Pathol Med; 2006 Jan; 35(1):19-24. PubMed ID: 16393249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutations in head and neck cancer.
    Beutner D; Klussmann JP; Guntinas-Lichius O
    N Engl J Med; 2008 Mar; 358(11):1194; author reply 1195. PubMed ID: 18337610
    [No Abstract]   [Full Text] [Related]  

  • 27. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
    Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
    Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of activin receptor-like kinase 1 among patients with head and neck cancer.
    Chien CY; Chuang HC; Chen CH; Fang FM; Chen WC; Huang CC; Huang HY
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):965-73. PubMed ID: 23447486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma.
    Lapke N; Lu YJ; Liao CT; Lee LY; Lin CY; Wang HM; Ng SH; Chen SJ; Yen TC
    Oncotarget; 2016 Jul; 7(28):44194-44210. PubMed ID: 27283772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 mutation, allelism and survival in non-small cell lung cancer.
    Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
    Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
    Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
    Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
    Li VD; Li KH; Li JT
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer.
    Erber R; Conradt C; Homann N; Enders C; Finckh M; Dietz A; Weidauer H; Bosch FX
    Oncogene; 1998 Apr; 16(13):1671-9. PubMed ID: 9582015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
    Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
    Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma.
    Gunduz E; Gunduz M; Beder L; Nagatsuka H; Fukushima K; Sutcu R; Delibas N; Yamanaka N; Shimizu K; Nagai N
    Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):254-60. PubMed ID: 19289703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.
    Masica DL; Li S; Douville C; Manola J; Ferris RL; Burtness B; Forastiere AA; Koch WM; Chung CH; Karchin R
    Hum Genet; 2015 May; 134(5):497-507. PubMed ID: 25108461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of p53 protein is common in premalignant head and neck lesions.
    Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
    Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
    Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
    OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.